Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This genomic locus is a **pseudogene** with no known protein-coding function, annotated as similar to part of SMT3 suppressor of mif two 3 (yeast). SMT3 suppressor of mif two 3 is a yeast gene related to the human SUMO (Small Ubiquitin-like Modifier) gene family. However, ENSG00000235190 itself does not encode a functional SUMO protein, nor does it participate in sumoylation or related cellular processes. Key context and supporting details: - The annotation as a "pseudogene similar to part of SMT3 suppressor of mif two 3" means it derives from sequence homology to a segment of a yeast gene (SMT3), but lacks protein-coding and functional elements. - There are multiple functional SUMO family members (such as SUMO2, SUMO3) in humans, which are involved in post-translational modification, but this pseudogene has no documented role and is not referenced as a target in biomedical literature. - GeneCards, HUGO Gene Nomenclature Committee, and related databases classify ENSG00000235190 specifically as a pseudogene—the most authoritative designation in genomic research. - It is not a member of any canonical therapeutic target families. Human protein-coding SUMO genes have aliases and defined molecular roles, which do not extend to this pseudogene. In summary, **ENSG00000235190 is not a drug target and is instead classified as a non-functional pseudogene with a nomenclature reflecting homology to the yeast SMT3 gene. All other fields related to therapeutic targeting, biological function, and druggability are not applicable**.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pseudogene similar to part of SMT3 suppressor of mif two 3 (yeast).